News | June 21, 2021
Zydus and Bayer announce extension of their JV
Bayer Zydus Pharma will continue to operate in core therapies with new products in the pipeline
Bayer Zydus Pharma will continue to operate in core therapies with new products in the pipeline
The turnover of its NPNC Formulations Division (IKKT Undertaking) for FY 2020-2021 is Rs.21.33 Cr
The next phase of growth in pharma depends on the industry-oriented workforce, risk investment, academic revamp, and creation of R&D hubs, say experts .
While top industry leaders are optimistic about the growth, they expect the special incentives and regulatory streamlining from the government’s side
Subscribe To Our Newsletter & Stay Updated
